Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31601867 | 1.00 | ALOX5 (0.47) | ALOX5MGLLFAAHGAARAB9A | |
| SCHEMBL31601937 | 1.00 | ALOX5 (0.47) | ALOX5MGLLFAAHGAARAB9A | |
| SCHEMBL31601944 | 1.00 | ALOX5 (0.47) | ALOX5MGLLFAAHGAARAB9A | |
| SCHEMBL31602042 | 1.00 | ALOX5 (0.47) | ALOX5MGLLFAAHGAARAB9A | |
| SCHEMBL3732638 | 1.00 | ALOX5 (0.47) | ALOX5MGLLFAAHGAARAB9A | |
| SCHEMBL24072918 | 1.00 | ALOX5 (0.47) | ALOX5MGLLFAAHGAARAB9A | |
| SCHEMBL3728710 | 1.00 | ALOX5 (0.47) | ALOX5MGLLFAAHGAARAB9A | |
| SCHEMBL10792403 | 1.00 | ALOX5 (0.47) | ALOX5MGLLFAAHGAARAB9A | |
| SCHEMBL31602003 | 1.00 | ALOX5 (0.47) | ALOX5MGLLFAAHGAARAB9A | |
| SCHEMBL31602071 | 1.00 | ALOX5 (0.47) | ALOX5MGLLFAAHGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103417423-B | Cu, Zn-rhSOD cosmetic composition that a kind of freckle removing and whitening is crease-resistant | SHANGHAI YUHUA LIFE TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2015-12-23 | — | — | CN | claimed |
| EP-2531229-B1 | MEDICINE PRODUCT WITH A PARTICLE-FREE COATING RELEASING AN ACTIVE SUBSTANCE | HEMOTEQ AG (DE) | 2014-12-31 | — | — | EP | claimed |
| CN-103417423-A | Cu and Zn-rh SOD cosmetic composition for removing freckle, whitening skin and resisting wrinkles | SHANGHAI YUHUA LIFE TECHNOLOGY DEV CO LTD | 2013-12-04 | — | — | CN | claimed |
| US-20090215888-A1 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2009-08-27 | — | — | US | claimed |
| CN-101296691-A | transdermal drug delivery dosage form | NUVO RES INC (CA) | 2008-10-29 | — | — | CN | claimed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | claimed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | claimed |
| WO-2007098591-A2 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2007-09-07 | — | — | WO | claimed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | claimed |
| US-20050095283-A1 | Compositions and methods for topically treating diseases | APHIOS CORPORATION | 2005-05-05 | — | — | US | claimed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | claimed |
| US-12589095-B2 | Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient | PRIMO PHARMATECH LLC (US) | 2026-03-31 | — | — | US | disclosed |
| US-12558312-B2 | Solid dosage form for transmucosal drug delivery | PRIMO PHARMATECH LLC (US) | 2026-02-24 | — | — | US | disclosed |
| EP-3735988-B1 | SUBLINGUAL FILMS | SUMITOMO PHARMA AMERICA INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | disclosed |
| EP-0391168-A1 | Use of N-alkyl-lactams for inhibiting crystallization | BAYER AG (DE) | 1990-10-10 | — | — | EP | disclosed |
| EP-0356382-A2 | Multilayer plaster | CIBA-GEIGY AG (CH) | 1990-02-28 | — | — | EP | disclosed |
| US-4886545-A | IMPROVE DELIVERY OF PLANT NUTRIENTS | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1989-12-12 | — | — | US | disclosed |
| US-4716060-A | ACYCLIC OR HETEROCYCLIC TERTIARY AMIDE | RAJADHYAKSHA VITHAL J (US) | 1987-12-29 | — | — | US | disclosed |
| US-4716060-A | ACYCLIC OR HETEROCYCLIC TERTIARY AMIDE | RAJADHYAKSHA VITHAL J (US) | 1987-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589095-B2 | Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient | OXTR, CCKBR, HTR2B | ALOX5 458/4885MGLL 482/4885FAAH 467/4885 |
| US-12558312-B2 | Solid dosage form for transmucosal drug delivery | AANAT, MTNR1B, CHLSN | ALOX5 746/4885MGLL 1998/4885FAAH 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.